News

Genomenon Report Reveals Gene Fusion Data a Critical Factor in Cancer Diagnostics and Drug Development

Genomenon Report Reveals Gene Fusion Data a Critical Factor in Cancer Diagnostics and Drug Development

Genomenon has released a research report detailing clinically significant fusion genes reported through April 2019. Fusion genes have long been known to play an important role in the development of cancer. Identifying and documenting each newly discovered fusion is crucial in both patient diagnosis and the development of precision medicines (targeted therapeutics). The report was compiled using research data found by the Mastermind Genomic Search Engine.

Genomenon used Mastermind to compile a comprehensive knowledgebase of literature describing gene fusions in order to analyze the data and relate the findings in the report. This is the most exhaustive fusion gene knowledgebase in existence, due to the completeness of the Mastermind literature database and the way Mastermind employs Machine Learning (ML) and Artificial Intelligence (AI) to organize and present the data.

The report includes:

  • Top Fusion Partners by Number of Articles
  • 
New Fusion Genes in Cancer for 2019



The data reveals:

  • Over 140 novel gene fusions were found across nearly 500,000 newly published scientific articles containing genomic content in 2018
  • Eleven novel fusions involved in the genesis of multiple cancer types have been found in newly published scientific articles in of April 2019
  • Both the number of articles describing novel (new) fusions and the number of articles describing all known fusions have experienced a relatively constant increase from 1987 to 2018, indicating a need to stay current with newly published information

Click here to read the full pdf.